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p38 Mitogen-Activated Protein Kinase Controls
Two Successive Steps During the Early
Mesodermal Commitment of Embryonic Stem Cells
Emilie Barruet,1 Ola Hadadeh,1 Franck Peiretti,1 Vale´rie M. Renault,1 Yasmine Hadjal,1 Denis Bernot,1
Roselyne Tournaire,2 Didier Negre,3–5 Ire`ne Juhan-Vague,1 Marie-Christine Alessi,1 and Bernard Bine´truy1
Embryonic stem (ES) cells differentiate in vitro into all cell lineages. We previously found that the p38 mitogen
activated kinase (p38MAPK) pathway controls the commitment of ES cells toward either cardiomyogenesis
(p38 on) or neurogenesis (p38 off ). In this study, we show that p38a knock-out ES cells do not differentiate into
cardiac, endothelial, smooth muscle, and skeletal muscle lineages. Reexpression of p38MAPK in these cells
partially rescues their mesodermal differentiation defects and corrects the high level of spontaneous neuro-
genesis of knock-out cells. Wild-type ES cells were treated with a p38MAPK-specific inhibitor during the dif-
ferentiation process. These experiments allowed us to identify 2 early independent successive p38MAPK
functions in the formation of mesodermal lineages. Further, the first one correlates with the regulation of the
expression of Brachyury, an essential mesodermal-specific transcription factor, by p38MAPK. In conclusion, by
genetic and biochemical approaches, we demonstrate that p38MAPK activity is essential for the commitment of
ES cell into cardiac, endothelial, smooth muscle, and skeletal muscle mesodermal lineages.
Introduction
Embryonic stem (ES) cells are pluripotent and retain thepotential for unlimited proliferation. Transplantation of
ES cells or their derivatives has been proposed as a future
therapy for various human diseases. However, molecular
mechanisms governing ES cell self-renewal and their com-
mitment into a specific lineage are poorly understood, and
their comprehension is necessary to improve the efficiency of
differentiation into specific lineages.
Self-renewal of mouse ES cells is dependent on intracel-
lular pathways initiated by the leukemia inhibitory factor
(LIF), by either serum or bone morphogenetic protein 2 or 4,
and by a complex interplay between specific epigenetic
processes, miRNAs, and transcription factors involved in the
development of the embryo, such as Oct4, Nanog, Sox2, or
FoxD3 (for review, see [1]). Removing LIF and adding ap-
propriate differentiation reagents result in the commitment
of ES cells into a variety of mature differentiated cell types,
including cardiac cells, skeletal muscle cells, neurons, or
adipocytes (for review, see [2,3]). ES cell differentiation can
be achieved by a wide variety of experimental protocols that
lack or include fetal bovine serum (FBS) and the use of
specific inducers such as the potent morphogen retinoic acid
(RA). The 107 mol=L RA treatment between the second and
fifth day is necessary for ES cell differentiation into neurons
and adipocytes [4–6]. In contrast, ES cell differentiation in the
absence of RA yields efficient differentiation to cardiomyo-
cytes with few neurons [4,7]. It is very likely that different
differentiation protocols and inducers will selectively
activate distinct signaling pathways that turn on cell lineage-
specific genetic programs to bring about the observed en-
richment in differentiated cell populations. Yet, the precise
molecular process of these signaling pathways controlling
cell differentiation of ES cells remains poorly understood.
p38 mitogen activated kinase (p38MAPK), extracellular
signal-regulated kinase (ERK), and c-Jun NH2-terminal kinase
( JNK) are conserved members of signal transduction path-
ways activated in response to growth factors or environ-
mental stresses [8]. ERK appears to play a major role in cell
proliferation and differentiation, whereas JNK is involved
in apoptosis. The p38MAPK family includes 4 members
( p38a, p38b, p38d, and p38g). These proteins are activated
by phosphorylation in response to osmotic stress, UV, and
various cytokines involved in inflammatory responses.
p38MAPKs, mainly p38a, have been proposed to regulate
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several cellular processes, such as proliferation, cell survival,
and differentiation [9]. Further, p38MAPK is directly involved
in the differentiation and=or survival of several cell types,
including neurons, endothelial cells, and myoblasts [10–12].
However, these studies analyzed the role of p38MAPK in the
terminal differentiation of established cell lines and primary
cultures; therefore an early p38MAPK role in the formation
of a given lineage cannot be evidence by these approaches.
Deletion of the p38a gene leads to early embryonic lethality
between 11.5 and 12.5 days due to erythropoiesis deficiency
[13] and=or to abnormal placental development [14], demon-
strating an essential role of p38MAPK in development. In
this case, the early embryonic lethality impairs the unveiling
of a potential role of this kinase pathway later on during
development. Therefore, analysis of ES cell differentiation
represents a unique experimental model to dissect p38MAPK
functions from undifferentiated ES cells to well-differentiated
cells.
In ES cells, p38a accounts for most of p38MAPK activity
because p38a= ES cells present no remaining p38MAPK
activity [15]. Interestingly, we previously found that, at
the opposite of wild-type (wt) ES cells, this knock-out (KO)
cell line spontaneously form neurons and are impaired in
cardiomyocyte formation. We found similar results by
studying the effects of the highly specific p38MAPK che-
mical inhibitor PD169316; demonstrating that p38MAPK
activity constitutes an early switch in ES cell commitment
into neurogenesis (p38 off ) versus cardiomyogenesis (p38
on) [16].
As this regulation takes place at the onset of the differ-
entiation process, in this study, we investigated the role of
p38MAPK in the ES cell commitment into other mesodermal
lineages potentially important for cellular therapy, such as
endothelial lineage, smooth muscle, and skeletal muscle. We
found that p38MAPK is necessary early for these differenti-
ations and that this requirement can be dissected into 2 in-
dependent successive steps.
Materials and Methods
Differentiation of ES cells
Mouse ES cells CGR8 [17] were grown on gelatin-coated
plates, as well as the 15= ES cells [18] after adaptation on
gelatin. 1= cells [18] were grown on MEF feeder cells
treated with 10 mg=mL mitomycin C for 3 h. For embryoid
body (EB) formation at day 0, 1103 ES cells were aggre-
gated in hanging drops (20 mL) without LIF, as described
previously [17]. For cardiomyocyte, neuron, and myotube
formation, EBs were cultivated in suspension until day 7
and then plated on gelatin-coated 6-well plate as already
described [16, 19]. Cardiomyocytes (beating cells) and
neurons (cells with neurites) were visible at day 12 and
myotubes (spontaneous contractile polynucleated myo-
tubes) at day 26. Quantification was given as the percentage
of EBs with cardiomyocytes, neurons, or myotubes. As for
the endothelial and smooth muscle differentiation, EBs
were plated on gelatin-coated 6-well plates or on 5mg=mL
Matrigel-coated 24-well plates (BD Biosciences) at day 3
and the media were changed every 2 days until day 12.
During EB differentiation, 10 mmol=L of the p38 inhibitor
PD169316 (Sigma-Aldrich) was added to the culture media
at different periods of time.
Western blot analysis
For p38MAPK protein analysis, EBs were lysed as previ-
ously described [17]. Samples (30 mg) were separated by
SDS–polyacrylamide gel electrophoresis on a 10% gel (In-
vitrogen) and transferred onto polyvinylidene difluoride
membranes (Millipore). Membranes were incubated with
antibodies against either all p38MAPK isoforms, MAPKAP-
K2, MAPKAPK2phospho (Cell Signalling Technology),
ERK2, or HA epitope (Santa Cruz).
Immunofluorescence staining
Differentiated EBs were washed and fixed at day 7 in 3%
paraformaldehyde for 15min at room temperature. Cell
membranes were permeabilized in phosphate-buffered
saline (PBS) with 0.1% Triton X-100 for 15min at room
temperature and incubated with a monoclonal anti-CD31=
PECAM (eBioscience), an anti-Troponin T (CT3), or an anti-
MHC (MF2Ds) (DSHB) in PBSþ 10% FBS for 1 h. After 3
washes in PBS, cells were incubated with anti-mouse
ALEXA488 or ALEXA546 (Invitrogen) for 1 h at room tem-
perature. Cell imaging was performed using a Nikon
microscope Eclipse 90I. Z-stack pictures were obtained by
using a Nikon Digital Sight DS-1QM camera controlled by
NIS element AR software (Nikon).
Flow cytometry
EBs were dissociated into single-cell suspensions by trypsi-
nization. Following awashwith 10% FBS=Dulbecco’smodified
Eagle’s medium, cells were permeabilized with 0.2% Tri-
ton=PBS buffer for 10min at room temperature. Cellswere then
stained with an a-cardiac Troponin T (CT3) antibody or an a-
Myogenin (FD5) antibody at 1:10 dilution in 5% FBS=PBS
(DSHB) for 1h. Following washes with 5%FBS=PBS, cells were
incubated with an anti-mouse IgG secondary antibody con-
juguated to PE (1:100 dilution in 5% FBS=PBS; Beckman
Coulter) for 30min in the dark. After additional washes in PBS,
cells were resuspended in 500mL PBS and analyzed on an
FC500 Flow cytometer using CXP software (Beckman Coulter).
For each sample, at least 5,000 cells were analyzed. Cursor for
positive fluorescent cells was placed, such as 95% of events
were excluded (first decade)when an isotype IgG antibodywas
used. Results are given as percentage corresponding to positive
fluorescent cells included in the region defined by the cursor.
RNA analysis
Total RNA was prepared using trizol reagent (Invitrogen).
Real-time reverse transcription-polymerase chain reaction
(RT-PCR) was performed with the ABI Prism7300 (Applied
BioSystems) and Taqman or Mesa Green MasterMix (Euro-
gentec). The relative amounts of different mRNAs were
quantified by using the comparative CT method (2(DDCT)).
36B4 was used as housekeeper transcripts and gene expres-
sions were normalized using 36B4 RNA levels. Primer se-
quences are given in Supplementary Table S1 (Supplementary
Data are available online at www.liebertonline.com=scd).
Plasmids
Two sequences of chromatin insulator were added to the
CAGop plasmid [20] using SacI restriction sites (pCAG-op-
1234 BARRUET ET AL.
Ins2X). The pcDNA3-p38a vector containing the human p38a
cDNA carrying an HA tag was a gift from Dr. Engelberg,
Jerusalem, Israel. The pCAG-op-Ins2X-p38a was generated
by inserting a KpnI-KpnI fragment from the pcDNA3-p38a
into the pCAG-op-Ins2X.
Generation of ES cell lines
The 1= and 15= ES cell lines were cotransfected with
the pGK-HygroR and pCAG-op-Ins2X-p38a, at a 10:1 ratio,
using the FuGene HD transfection system (Roche Molecular
Biochemicals) according to the manufacturer’s protocol, and
selected in 100 mg=mL hygromycin (Invitrogen) to generate
p38= ES cell clones expressing exogenous p38a.
In the case of 1= cell line, transfection was realized onto
mitomycin C-treated MEF feeder cells. Stable, hygromycin-
resistant MEF cells were obtained by transduction with the
CHC vector, an MLV retrovirus vector coding the hph cDNA
[21] using an MOI of 6UI=cell, followed by hygromycin
selection (100 mg=mL). Moloney leukemia virus (MLV)-based
vector was generated by transient transfection of 293T cells
as previously described [22].
Statistical analyses
All experiments were performed at least 3 times. All data
are expressed as the mean standard error of the mean.
Treatments were compared with their respective controls
and significant differences among the groups were deter-
mined using unpaired Student’s t-test. A P-value of <0.05
was taken as an indication of statistical significance.
Results
p38a= ES cells do not differentiate
into endothelial, smooth muscular, and skeletal
muscular mesodermal lineages
In addition to cardiomyogenesis and neurogenesis, endo-
thelial and smooth muscle differentiations are among the
earliest lineages to arise, both in vivo, during embryo for-
mation, and in vitro, during ES cell differentiation [23]. In the
present study, we compared 2 p38a-homozygote KO ES cell
lines [18], clones 1= and 15=, to the standard CGR8 ES
cell line. Undifferentiated cells were induced to differentiate
by the technique of EB formation [16] and RNAs were ex-
tracted by day 12 or 26 and gene expression for specific cell
lineage markers was evaluated by real-time RT-PCR. Similar
to what we previously found, spontaneous cardiomyogen-
esis was drastically impaired in these KO cells when com-
pared with wt CGR8 cells. At day 12 of differentiation,
cardiac phenotype, quantified by both the percentage of EB
outgrowths with contractile cells and expression of the car-
diac specific markers Nkx2.5 and GATA-4, was significantly
reduced in the 2 KO cell lines when compared with wt cells
(Supplementary Fig. 1A–C). In wt CGR8 cells, neuron for-
mation by day 12 was not spontaneous and was strictly
dependent on an RA treatment between days 3 and 5 [16]. In
contrast, 35%–50% of EBs of the cell line 1= form neurons
by day 12 of the differentiation protocol, with or without RA
treatment, and express high levels of the neuronal specific
marker MAP2, measured by real-time RT-PCR (Supple-
mentary Fig. 2A, B and Fig. 5). Surprisingly, the 15= cell
line does not show any neuronal differentiation tendency,
even after RA treatment (Supplementary Fig. 2A, B). One
could hypothesize that, in this cell line, neurogenesis is in-
hibited by an unknown molecular event, independent of KO
of the p38a gene.
To test endothelial differentiation we used a previously
established protocol [24]. Endothelial phenotype was char-
acterized by anti-PECAM (also known as CD31) immuno-
fluorescence (Fig. 1A, left column) and formation of typical
vessel-like structures on Matrigel (Fig. 1A, right column).
Endothelial differentiation was also analyzed by measuring
the expression levels of endothelial-specific markers. mRNA
expression profiles of Flk-1 and Tie2 genes show a sharp and
robust increase after day 3 or 5 of differentiation, respec-
tively, and an increasing Flk-1 expression until day 12,
whereas Tie-2 expression diminishes after day 7 (Fig. 1B, C).
The expressions of the endothelial markers PECAM and
vWF show biphasic expression profiles, decreasing to low
levels from day 0 to day 3, and then a progressive increase
from day 3 to day 7 (Supplementary Fig. S1D, E). The
PECAM profile is very similar to what has been already
described in other ES cell lines [25]—the expression level
found in undifferentiated cells was not correlated to endo-
thelial differentiation. When induced to differentiate on either
gelatin or Matrigel from day 3, p38= cells show almost no
vessel-like structures (Fig. 1A); this lack of differentiation was
characterized by the blockade of gene expression of the Flk-1,
Tie-2, vWF, and CD31 markers (Fig. 1B, C and Supplementary
Fig. S1D, E). These results present a discrepancy with those
published by Guo et al., who showed that p38a KO ES cells
can differentiate toward endothelial cells [26]. However, in
this study, quantification of expression of endothelial mark-
ers was performed in a different KO ES cell line and, more
importantly, only 2 markers were tested, one (PECAM) pre-
senting no variation between KO and wt cells, whereas the
other (VEcad) was found significantly downregulated in KO
cells, suggesting an endothelial defect of these cells.
In parallel to endothelial cells, these culture conditions lead
also, in the same Petri dishes, to the differentiation of vascular
smooth muscle cells, which participate in the formation of
vessel-like structures [24,27,28]. Our culture conditions are
also permissive for this differentiation, as indicated by the
high level of gene expression in wt ES cells at days 7–12 of
the specific marker a-smooth muscle actin (Fig. 1D). Similar to
endothelial differentiation, formation of the smooth muscle
cell lineage was also impaired in p38a KO cells (Fig. 1D).
Our results suggest that, in addition to cardiomyogenesis,
the p38MAPK pathway is required for the formation of en-
dothelial and smooth muscle cell lineages.
We then analyzed the potential role of p38MAPK in me-
sodermal lineages formed later on during development, such
as skeletal myogenesis. After 26 days of induction, wt ES
cells form spontaneous contractile myotubes (Supplementary
Fig. S1F) and express specific skeletal muscular genes such as
Myosin Heavy Chain 1 (MyH1; Fig. 1E) and Myogenin
(Supplementary Fig. S1G). In contrast, both the 2 p38a KO
cell lines were impaired in their skeletal myogenic capacities,
reduced number of EB-forming myotubes and reduced ex-
pression of markers (Fig. 1E and Supplementary Fig. S1F, G).
These results demonstrate that the p38MAPK pathway is
also required for formation of skeletal muscle, a late-forming
mesodermal lineage.
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Construction of p38a KO cell derivatives expressing
exogenous p38 proteins
To demonstrate that mesodermal differentiation defects of
p38a= cell lines are due to the KO of p38, we reexpressed
p38MAPK in these KO cells. We used an expression vector
for an HA-tagged p38a cDNA under the control of the
synthetic CAG promoter, known to be very potent in ES cells
before and upon differentiation [20,29]. We isolated and
analyzed p38-reexpressing ES derivatives from KO cell lines:
clone R1-1 for the cell line 1= and R15-1 and R15-2 for the
cell line 15=. In the presence of LIF, all these cell lines
display an ES morphology (data not shown) and express
levels of Oct4 and Nanog, major specific genes of plur-
ipotency, similar to wt and p38a KO ES cells (Supplementary
Fig. S3A, B). We first checked the persistence of transgene
expression during the differentiation process by real-time
RT-PCR. As shown in Supplementary Fig. S3C, all cell lines
conserve their p38 cDNA transgene expression from day 0 to
day 26. Protein expression levels were analyzed by western
blots with either anti-p38 total (a-p38tot) or anti-HA anti-
bodies and anti-ERK antibodies as control (Fig. 2). Reex-
FIG. 1. Wild-type but not
p38a= ES cells differenti-
ate toward endothelial cells,
smooth muscle cells, or
skeletal myotubes. (A) EBs
from 1= and 15=, KO for
p38a, and wt CGR8 ES cells
were plated on gelatin (left
column) or Matrigel (right
column) at day 3 of differen-
tiation. Cells were either
analyzed by immunofluores-
cence using anti-PECAM an-
tibodies (400 magnification;
left column) or photographed
using a phase-contrast mi-
croscope (right column) at day
7 of differentiation (magnifi-
cation was 100 for wt cells
and 200 for p38 KO cells).
Representative results are
shown; arrows indicate the
vessel-like structures formed
on Matrigel. In parallel simi-
lar experiments, for endothe-
lial and smooth muscle
differentiations, mRNAs
were extracted at days 3, 5, 7,
and 12 and analyzed by real-
time RT-PCR for the expres-
sion of endothelial markers,
Flk-1 (B) and Tie-2 (C), and
the smooth muscle cell mar-
ker alpha-SMA (D). For
skeletal myogenesis analysis,
the expression of the skeletal
myogenic marker MyH1 was
evaluated by day 26 for each
cell line (E). Results are ex-
pressed in arbitrary units,
with the values of wt CGR8
at day 0 taken as 1, and are
the means SEM of at least 3
independent experiments.
Significance between wt and
KO cells is given as *P< 0.05
and **P< 0.01. ES, embryonic
stem; EB, embryoid body; wt,
wild-type; KO, knock-out;
alpha-SMA, alpha-smooth
muscle actin; RT-PCR, re-
verse transcription-polymer-
ase chain reaction; MyH1, myosin heavy chain-1; SEM, standard error of the mean. Color images available online at
www.liebertonline.com=scd
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pressing cell lines present only partial restoration of wt en-
dogenous p38 protein levels, between 23% and 46% of levels
present in wt cells, at day 4 of differentiation (Fig. 2); similar
results were obtained at days 0, 12 (data not shown), and 20
(Supplementary Fig. S3D). As a functional test for investi-
gating the restored activity of the p38MAPK pathway, we
analyzed the phosphorylation status of a known direct
p38MAPK target: the MAPK activated protein kinase-2
(MAPKAP-K2) [9]. Western blots using anti-MAPKAP-K2
total or phosphorylated proteins demonstrated that
p38MAPK KO cells display the remaining proportion of
phosphorylated MAPKAP-K2 proteins comprised between
16% and 21% of levels in wt cells (Fig. 2). These low but not
null levels indicate that, although the phosphorylation of
MAPKAP-K2 protein is a good indication of a-p38MAPK
activity, this protein can be targeted by other kinases. We
found that incubation of wt cells with the p38MAPK inhib-
itor leads to only 50% reduction in MAPKAP-K2 phosphor-
ylation (Fig. 2); this result could also be due to alternative
pathways phosphorylating this protein. Interestingly, reex-
pressing cell lines present intermediate levels (32%–61%)
between KO and wt, compatible with their partial restoration
of p38MAPK expression (Fig. 2).
Reexpression of p38 protein in p38a KO cell lines
rescues their defects in mesodermal differentiation
We then analyzed the reexpressing cell lines for their
differentiation capacities toward the cardiac, endothelial,
smooth muscular, skeletal muscular, and neuronal lineages.
Cardiomyogenesis was evaluated by the percentage of
EBs with beating cells (Fig. 3A), Gata-4 (Fig. 3B) and Nkx2.5
expressions (Supplementary Fig. S4A), and flow cytometry
with anti-Troponin T antibodies (Fig. 3C and Supplementary
Fig. S4C) at day 12. Remarkably, cardiomyocytes formation
was significantly, but partially, restored in the 3 reexpressing
clones. This restored cardiomyogenic phenotype was also
illustrated by immunofluorescence analysis with anti-Tro-
ponin T antibodies (Fig. 3D and Supplementary Fig. S4D).
Likewise, analysis of Tie-2, Flk-1, and alpha-smooth
muscle actin expression levels show that endothelial and
smooth muscle lineages are also partially, but significantly,
restored in reexpressing clones (Fig. 4A, B and Supplemen-
tary Fig. S4B).
Skeletal myogenesis was evaluated by measuring the
percentage of EBs with contractile myotubes, by Myogenin
and MyH1 expressions, and by flow cytometry with anti-
Myogenin antibodies at day 26. Strikingly, the clone R1-1
displays differentiation capacities completely restored to wt
levels (Fig. 4C, D and Supplementary Fig. S5). The 2 other
reexpressing clones, R15-1 and 2, present partial restored
skeletal myogenic phenotypes (Fig. 4C–E and Supplemen-
tary Fig. S5A). This restored skeletal myogenic phenotype
was also illustrated by immunofluorescence analysis with
anti-MHC antibodies (Fig. 4F and Supplementary Fig. S5C).
Finally, neuronal differentiation, measured by the per-
centage of EBs with neuron outgrowths and MAP2 expres-
sion level, was analyzed in these cells. We found that the
spontaneous neuron formation and the high level of MAP-2
expression characteristic of 1= cells are completely in-
hibited in R1-1 cells, back to wt levels, thereby restoring the
p38 inhibitory effect toward this lineage (Fig. 5). Already
being very low in 15= cells, neurogenesis was not modified
in R15-1 and 2 derivatives (Supplementary Fig. S2).
Altogether our data show that, despite the only partial
reexpression of wt p38MAPK protein level, the p38MAPK
KO-derivative clones are profoundly modified in their dif-
ferentiation capacities. p38MAPK reexpression in KO cells
restores, to various degrees, all wt mesodermal and neuronal
phenotypes.
Taking into account the analysis of neurogenesis, our
results suggest that, in addition to the p38a KO, variable
FIG. 2. Molecular characterization
of p38a KO cell derivatives partially
reexpressing p38a protein. p38a
protein expression at day 4 of dif-
ferentiation of various ES cell lines
was analyzed by western blotting
with pan-p38 (a-p38), a-HA, a-
phosphoMAPKAP-K2 (a-MK2-p),
and a-MAPKAP-K2 total (a-MK2)
antibodies. Membranes were re-
probed with a-ERK2 antibodies as
loading control. Migrations of en-
dogenous p38 and HA-p38 proteins
are indicated (right-hand side). Ana-
lysis of wild-type CGR8 cells (WT),
treated (Inh) or not with the p38
specific inhibitor, the 1= and 15=
p38 KO cell lines, and their deriva-
tives R1-1 and R15-1 and 2 is
shown. p38 protein expression sig-
nals obtained with pan-p38 anti-
bodies were quantified, corrected for
equivalent ERK expression, and expressed as percentage of the endogenous p38 expression found in CGR8 wt cells. Phos-
phoMAPKAP-K2-protein expression signals were quantified, corrected for equivalent total MAPKAP-K2 expression, and
expressed as percentage of the expression found in CGR8 wt cells. a-HA, a-hemaglutinin antigen; MAPKAP-K2, MAPK,
mitogen activated protein kinase-activated protein kinase-2; a-ERK2, a-extracellular signal-regulated kinase 2.
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FIG. 3. Reexpression of p38 protein in KO cell lines partially rescues their defects in cardiomyogenesis. EBs from wt CGR8,
1=, R1-1, 15=, R15-1, and R15-2 ES cells were plated on gelatin at day 7 of differentiation and analyzed at day 12. (A)
Cardiomyocyte phenotype was expressed as the percentage of EBs with beating cell areas. Values are expressed as means of
at least 3 independent experiments SEM. (B) mRNAs were analyzed by real-time RT-PCR for expression of the specific
cardiac marker GATA-4. Results are expressed in arbitrary units, with the values of wt CGR8 at day 12 taken as 1, and are the
means SEM of at least 3 independent experiments. Significance between KO and reexpressing cells is given as *P< 0.05,
**P< 0.01, and ***P< 0.001. (C) Differentiated cells at day 12 were analyzed by flow cytometry analysis of Troponin T.
A histogram representative of 3 independent experiments is shown. For each experiment, control value (irrelevant) was
determined as no more than 5% of positivity. (D) Differentiated cells at day 12 were analyzed by immunofluorescence using
anti-Troponin T antibodies (magnification: 100). Nuclei were stained with DAPI. DAPI, 40,6-diamidino-2-phenylindole.
Color images available online at www.liebertonline.com=scd
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molecular characteristics could participate in the differenti-
ation defects of KO cell lines. One can hypothesize that these
differences could be due to genetic instability of KO cells
leading to variability in their biological responses.
p38MAPK activity is required for 2 early successive
steps in mesodermal commitment of ES cells
To bypass these potential genetic differences, we analyzed
the role of p38MAPK by directly inhibiting its activity in dif-
ferentiating wt ES cells with the specific chemical inhibitor
PD169316. Further, inhibitor treatment of differentiating ES
cells from day 3 to day 5 blocks the spontaneous peak of
p38MAPK activity observed at that step [16]. The inhibitorwas
applied in 3 different conditions: (i) all the time of differentia-
tion, from day 0 to day 7, 12, or 26 (d0–d7, d0–12, d0–d26,
depending of the lineage analyzed); (ii) only from day 0 to day
3 (d0–d3); (iii) from day 3 to day 5 (d3–d5) (Fig. 6A). We
focused our study on the d0–d5 period because inhibition of
p38MAPK after day 5 has no effect (Supplementary Fig. S6).
Cardiomyogenesis of ES cells is completely inhibited by
either the d0–d12 or d3–d5 treatment (Fig. 6B–E and Sup-
plementary Fig. S7A). This inhibition was similar to what
was observed in the 1= and 15= KO cell lines. In con-
trast, the d0–d3 treatment has a very modest effect, reducing
the percentage of EBs with beating cells at day 12 from 75%
in control treated cells to 40% and without any effect on gene
expression of cardiac markers. Therefore, the major effect on
cardiomyogenesis of inhibition of p38MAPK is restricted to
the d3–d5 period, coincidental to the spontaneous peak of
p38 kinase activity.
We then analyzed the effect of the p38 inhibitor on ES
endothelial and smooth muscle differentiation by day 7. In
contrast to that observed for cardiomyogenesis, the 3 dif-
ferent treatments were equally efficient to completely block
the expression of endothelial and smooth muscle markers
(Fig. 6F, G and Supplementary Fig. S7B).
Similar to endothelial and smooth muscle cell formation,
we found that wt ES cells require a continuous p38MAPK
activity between days 0 and 5 to differentiate, latter on, into
the skeletal myogenic lineage. The 3 different p38 inhibitor
treatments completely inhibit the formation of contractile
myotubes and expression of myogenic markers, evaluated at
day 26 (Fig. 7 and Supplementary Fig. S7C).
p38MAPK activity controls expression
of the mesodermal master gene Brachyury
In the mouse embryo, mesoderm is generated from the
epiblast through the process of gastrulation, which is initiated
at day 6.5 of gestation. The transcription factor-encoding
Brachyury gene is specifically expressed in nascent meso-
derm and downregulated as these cells differentiate into
skeletal muscle, cardiac muscle, blood, and endothelium. In
vivo studies have demonstrated the importance of Brachyury
in regulating cell fate decisions. Brachyury= mice die
shortly after gastrulation and display several mesodermal
abnormalities [30]. However, the role of this gene in ES cell
differentiation in vitro is unknown. Because our results
demonstrate the early requirement of p38MAPK in meso-
dermal commitment of ES cells, we hypothesized that this
effect could be mediated by regulation of Brachyury.
Brachyury gene expression was investigated between
days 0 and 7 of differentiation of wt, KO, and p38a reex-
pressing ES cells. As expected, expression of this gene is very
low in wt undifferentiated ES cells. Expression profile during
EB differentiation shows a peak of expression, centered at
day 3, of 32-fold the level at day 0, going down to the basal
level of undifferentiated cells by day 5 and staying low until
day 7 (Fig. 8). This profile is identical to the one described in
the work by Fehling et al. [31], using another wt ES cell line,
and is compatible with an important function for this gene in
ES cell commitment toward mesoderm lineages. In contrast
to wt cells, p38a KO ES cells present no peak of Brachyury
expression (Fig. 8A, B). This result is in line with the work of
Duval et al. [32], who found that Brachyury gene expression
is under the control of p38MAPK pathway. Our results in-
dicate that there is a correlation between mesodermal defects
of KO cells and low levels of Brachyury expression. How-
ever, both 1= and 15= reexpressing derivatives do not
recapitulate the Brachyury expression profile of wild-type ES
cells, expressing Brachyury levels slightly different to KO
cells only after day 4 (Fig. 8A, B). Therefore, these results
indicate that the restoration of mesodermal differentiation
capacities displayed by reexpressing cells cannot be ex-
plained by a rescue of Brachyury expression.
To precisely understand the role of p38MAPK in the reg-
ulation of Brachyury gene expression, we then analyzed the
effect of the p38 inhibitor treatment on wt ES cells during
differentiation (Fig. 8C). The d0–d7 treatment completely
blocks the expression of this gene, recapitulating the effect of
the genetic KO and showing a correlation between Brachy-
ury inhibition and blockade of mesodermal differentiation.
In contrast, the d3–d5 treatment has no effect on Brachyury,
leaving the peak of expression unchanged, centered at day 3.
Importantly, because this treatment is as efficient as the
d0–d7 in inhibiting mesodermal differentiation (Fig. 7), this
result demonstrates that p38MAPK can regulate the forma-
tion of mesodermal lineages independently of Brachyury
regulation. Surprisingly, the d0–d3 treatment blocks
Brachyury expression until day 3, but then its expression
increases and peaks at day 5 before going down by day 7.
This treatment blocks the formation of endothelial and
skeletal muscular lineages, leaving cardiomyogenesis almost
unchanged (Fig. 7); this indicates that cardiac cells can be
formed even if the peak of Brachyury expression at day 3 is
absent.
Discussion
By genetic and biochemical approaches we previously
described a role of p38MAPK as an early switch of ES cell
commitment into cardiomyocytes or neurons [16]. Either
gene deletion or specific inhibition of the peak of p38MAPK
activity, observed between days 3 and 5 during ES cell
differentiation, partially mimicked the cardiomyogenesis
inhibition by 107 mol=L RA treatment. In the present study,
we extended this observation to the endothelial, smooth
muscle, and skeletal muscle lineages and found that the
p38MAPK requirement can be dissected into 2 successive
steps during the differentiation process, one between days 0
and 3 and the second between days 3 and 5. We found that
the first step correlates with the p38MAPK regulation of
Brachyury gene expression.
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A role for p38a in various aspects of cardiomyogenesis,
including the regulation of cardiomyocyte differentiation,
apoptosis, and hypertrophy, has been described [33–35]. In-
terestingly, p38a= embryos present a massive reduction of
the myocardiac muscle attributed to a defect in placental
development [14]. By analysis of both p38a KO ES cells and
effects of biochemical inhibition of the pathway, we dem-
onstrate that p38MAPK is required for the cardiomyogenesis
of ES cells. Moreover, successive treatments of ES cells with
the p38 inhibitor show that the major effect of inhibition of
p38MAPK kinase activity on this lineage is evidenced during
the d3–d5 period.
In contrast to our results, a recent work described an
enhanced cardiomyogenesis of human ES cells by
a small molecular inhibitor of p38 MAPK [36]. This apparent
discrepancy could be due to different experimental param-
eters between the 2 studies: 2 different cellular models (hu-
man ES cells vs. mouse ES cells); different inhibitors
(SB203580 vs. PD169316), which are known to differently
affect ES cell differentiation [32]; and importantly, in human
ES cells these effects are concentration dependent, with an
inhibitory effect at high concentrations, similar to what we
found in mouse ES cells.
Circulating endothelial precursor cells provide an endog-
enous repair mechanism to counteract ongoing risk factor-
induced endothelial injury and to replace dysfunctional en-
dothelium [37]. p38MAPK has been involved in both the
control of endothelial precursor cell proliferation [38] and the
migration of mature endothelial cells [11]. Smooth muscle
cells are important contributors to blood vessel integrity. Our
study demonstrates that p38MAPK is crucial early on during
the differentiation process of ES cells toward the endothelial
FIG. 4. Reexpression of p38 protein in KO cell lines partially rescues their endothelial, smooth muscle, and skeletal muscle cell
defects. EBs from wt CGR8, 1=, R1-1, 15=, R15-1, and R15-2 ES cells were plated on gelatin at day 3 for endothelial or
smooth muscle cell differentiation or at day 7 for skeletal myogenesis and analyzed at day 7 for endothelial and smooth muscle
cells or at day 26 for skeletal myogenesis. mRNAs at day 7 were analyzed by real-time RT-PCR for expression of the endothelial
marker Tie-2 (A) and the smooth muscle marker a-SMA (B). (C) The ratio of EBs with spontaneous contractile myotubes was
evaluated by day 26 for each cell line; at least 50 different EBs per cell line were counted. Histogram shows the means SEM of
3 independent experiments. (D) mRNAs were analyzed by real-time RT-PCR for expression of the specific skeletal muscle
marker MyH1. Results are expressed in arbitrary units, with the values of wt CGR8 at day 0 (A, B) or day 26 (D) taken as 1, and
are the means SEM of at least 3 independent experiments. Significance between KO and reexpressing cells is given as
*P< 0.05, **P< 0.01, and ***P< 0.001. (E) Differentiated cells at day 12 were analyzed by flow cytometry analysis of Myogenin.
A histogram representative of 3 independent experiments is shown. For each experiment, control value (irrelevant) was
determined as no more than 5% of positivity. (F) Differentiated cells at day 12 were analyzed by immunofluorescence using
anti-MHC antibodies (magnification: 100). Nuclei were stained with DAPI. Color images available online at www
.liebertonline.com=scd
‰
FIG. 5. Reexpression of p38 protein in KO
cell lines inhibits their spontaneous neuro-
genesis. EBs from wt CGR8, 1=, and R1-1
ES cells were plated on gelatin at day 7 and
analyzed at day 12. (A) Neuronal phenotype
was expressed as the percentage of EBs with
neurons in outgrowths (means SEM of at
least 3 independent experiments). (B)mRNAs
were extracted at day 12 and analyzed by
real-time RT-PCR for expression of the spe-
cific neuronal marker MAP2. Results are ex-
pressed in arbitrary units, with the values of
wt CGR8 at day 12 taken as 1, and are the
means SEM of at least 3 independent ex-
periments. Significance is given as *P< 0.05.
(C) Differentiated cells at day 12 were pho-
tographed using a phase–contrast microscope
(magnification was 100 for upper and lower
panels and 200for middle panel). Color images
available online at www.liebertonline
.com=scd
p38 CONTROLS THE MESODERMAL COMMITMENT OF ES CELLS 1241
and smooth muscle lineages. In contrast to cardiomyogen-
esis, this signal transduction pathway is required continu-
ously between days 0 and 5 for the ES commitment of these
lineages. Our data are consistent with the p38MAPK path-
way constituting an important potential player in vessel re-
construction from ES cells.
To explain the role of P38MAPK in ES cell differentiation
toward cardiac, endothelial, and smooth muscle cells, one
simple hypothesis would be that this pathway targets a
precursor common to these lineages. For example, such
precursor could be located in defined structures that could be
represented in vivo by the hemangioblast, which has been
defined as the early embryonic structure capable to generate
both hematopoietic and vascular lineages [39,40]. This
structure is molecularly characterized by the coexpression,
during a limited period of time, of Brachyury and Flk-1
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genes. Interestingly, we also found these 2 genes to be reg-
ulated by p38MAPK in our cellular model. Whether Bra-
chyury and Flk-1 are the only p38MAPK targets required for
the control of hemangioblast formation leading to endothe-
lial and smooth muscle lineages necessitate further investi-
gations. However, the fact that cardiomyogenesis presents
sensitivity to the p38 inhibitor different from the other line-
ages suggests the existence of several distinct precursors.
Because the d3–d5 treatment with the inhibitor affects dif-
ferentiation without changing Brachyury gene expression,
we hypothesize that, at this precise step, p38MAPK regulates
critical unknown mesodermal regulators.
FIG. 6. p38MAPK activity is required for 2 early successive steps in mesodermal commitment of ES cells. EBs from wt CGR8
ES cells were differentiated in the presence or absence of PD169316 for different periods as indicated schematically in (A). For
cardiomyogenesis, EBs were plated at day 7 and analyzed at day 12 of differentiation. Cardiomyocyte phenotype was
expressed as the percentage of EBs with beating cell areas (means SEM of at least 3 independent experiments) (B). In these
experiments, mRNAs were extracted at day 12 and analyzed by real-time RT-PCR for expression of the specific cardiac
marker GATA-4 (C). Results are expressed in arbitrary units, with the values of control cells at day 12 taken as 1, and are the
means SEM of at least 3 independent experiments. Significance between control and treated cells is given as *P< 0.05,
**P< 0.01, and ***P< 0.001. (D) Differentiated cells at day 12 were analyzed by flow cytometry analysis of Troponin T. A
histogram representative of 3 independent experiments is shown. For each experiment, control value (irrelevant) was de-
termined as no more than 5% of positivity. (E) Differentiated cells at day 12 were analyzed by immunofluorescence using
anti-Troponin T antibodies (magnification: 100). Nuclei were stained with DAPI. For endothelial and smooth muscle cell
formation, EBs were plated at day 3 and mRNAs were analyzed at days 0, 3, 5, and 7 of differentiation by real-time RT-PCR
for expression of the specific endothelial marker Tie-2 (F) and the smooth muscle marker a-SMA (G). Results are expressed as
the percentage of the expression level in control cells at day 7 and are the means SEM of at least 3 independent experiments.
Significance between control and treated cells is given. Color images available online at www.liebertonline.com=scd
‰
FIG. 7. p38MAPK activity is required for 2 early successive steps in skeletal myogenesis of ES cells. EBs from wt CGR8 ES
cells were differentiated in the presence or absence of PD169316 for different periods as indicated schematically in Fig. 6A.
EBs were plated at day 7 and analyzed at day 26 of differentiation. (A) The ratio of differentiated EBs with spontaneous
contractile myotubes was evaluated for each cell line; at least 50 different EBs per cell line were counted. Histogram shows the
means SEM of 3 independent experiments. (B) In these experiments, mRNAs were extracted at day 26 and analyzed by
real-time RT-PCR for expression of the specific skeletal muscle marker MyH1. Results are expressed in arbitrary units, with
the values of wt CGR8 at day 26 taken as 1, and are the means SEM of at least 3 independent experiments. Significance
between control and treated cells is given as *P< 0.05, **P< 0.01, and ***P< 0.001. (C), Differentiated cells at day 12 were
analyzed by flow cytometry analysis of Myogenin. A histogram representative of 3 independent experiments is shown. For
each experiment, control value (irrelevant) was determined as no more than 5% of positivity. (D) Differentiated cells at day 12
were analyzed by immunofluorescence using anti-MHC antibodies (magnification: 100). Nuclei were stained with DAPI.
Color images available online at www.liebertonline.com=scd
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There is an abundant literature showing that p38MAPK
activity increased during myoblast differentiation and that
this pathway regulates the expression of muscle-specific
genes via the control of MyoD and MEF2 muscle-specific
transcription factors (for review, see [41]). In vivo, p38MAPK
is involved in the developing somite myotome of mice [42].
The p38 MAPK pathway is required for the activation of the
quiescent muscle precursor, the satellite cell [43], whereas
neither the ERK nor the JNK pathway is involved in the
skeletal myogenic process [44,45]. Importantly, myoblasts
lacking p38a are unable to differentiate and to form multi-
nucleated myotubes [46]. Our study extends the requirement
of p38MAPK in skeletal myogenesis to the early embryonic
events of this process. Particularly, analysis of muscle differ-
entiation capacities of either p38a KO ES cells or wt ES cells
treated by the p38 inhibitor demonstrated that this pathway is
required continuously between days 0 and 5 for skeletal
myogenesis.
Altogether our results demonstrate that the p38MAPK
activity is required continuously between days 0 and 5 for
cardiac, endothelial, smooth muscle, and skeletal muscle
mesodermal commitment and, conversely, inhibits neuro-
genesis. We were able to dissect this requirement into 2
successive steps: the first one between days 0 and 3 corre-
sponds to basal p38 activity necessary for the formation of
endothelial, smooth muscle, and skeletal muscle lineages and
correlates with regulation of Brachyury expression, whereas
the second step corresponds to the spontaneous peak of
p38MAPK activity between days 3 and 5 [16]; in addition to
the former mesodermal lineages, cardiomyogenesis is con-
trolled at this step.
Owing to the known biological role of Brachyury and the
effect of p38MAPK inhibition on the expression of this gene,
one can hypothesize that the d0–d3 p38MAPK biological
function in ES commitment is mediated by Brachyury.
However, the reexpressing cell lines, although rescuing the
mesodermal defects displayed by p38MAPK KO ES cells, do
not recapitulate wt Brachyury expression, suggesting that
this gene is not involved in this p38MAPK function. Im-
portantly, it is noteworthy that the mesodermal rescues and
the reexpressed p38MAPK protein levels are partial. There-
fore, it is possible that the peak of Brachyury expression at
day 3 requires wt p38MAPK levels and, in turn, that this
peak is necessary for the full mesodermal response of ES
cells. Further works on Brachyury regulation are necessary to
decipher the molecular links between p38MAPK, Brachyury,
and mesodermal commitment of ES cells.
Regarding the control of mouse ES cell differentiation, it is
noteworthy that the p38MAPK pathway displays unique
biological properties when compared with ERK and JNK
MAPK pathways. Indeed, we found that p38MAPK consti-
tutes a major switch between mesodermal lineages (p38 on)
and neurogenesis (p38 off), whereas the ERK pathway plays
a different control earlier, because ERK2 KO cells are blocked
in both mesodermal and neuronal differentiations [47], and
JNK is involved only in neurogenesis [48].
Owing to the fact that p38MAPK pathway controls ES cell
commitment toward mesodermal lineages, our results sug-
gest that the precise modulation of this pathway early on
during ES cell differentiation would help their use in re-
generative medicine by improving the efficiency of differ-
entiation into specific lineages.









































































FIG. 8. The Brachyury gene expression is regulated by
p38MAPK during ES cell differentiation. In (A and B), EBs
from wt CGR8, 1=, R1-1, 15=, R15-1, and R15-2 ES cells
were plated on gelatin at day 3 until day 7 of differentiation.
Similarly, EBs from wt CGR8 ES cells were induced to dif-
ferentiate in the presence or absence of PD169316 for different
periods as indicated in Fig. 6A (C). mRNAs were analyzed at
days 0, 3, 4, 5, and 7 by real-time RT-PCR for Brachyury
expression. Results are expressed in arbitrary units, with the
values of wt CGR8 at day 0 taken as 1, and are the means
SEM of at least 3 independent experiments. *Significance be-
tween wt and KO cells (A, B) or between day 0 versus day 3,
day 3 versus day 4, and day 4 versus day 5 (C). *P< 0.05,
**P< 0.01, and ***P< 0.001. #Significance between control and
treated cells (C). #P< 0.05 and ##P< 0.01. Color images
available online at www.liebertonline.com=scd
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